Literature DB >> 23377956

Comparison of the Seattle heart failure model and cardiopulmonary exercise capacity for prediction of death in patients with chronic ischemic heart failure and intracoronary progenitor cell application.

Joerg Honold1, Salvatore DeRosa, Ioakim Spyridopoulos, Ulrich Fischer-Rasokat, Florian H Seeger, David Leistner, Saskia Lotz, Wayne C Levy, Andreas M Zeiher, Birgit Assmus.   

Abstract

BACKGROUND: Despite many therapeutic advances, the prognosis of patients with chronic heart failure (CHF) remains poor. Therefore, reliable identification of high-risk patients with poor prognosis is of utmost importance. Cardiopulmonary exercise testing (CPET) provides important prognostic information by peak O2 uptake (peak VO2 ), maximal oxygen pulse (O2 Pmax), O2 uptake efficiency slope (OUES), and VE/VCO2 slope (VE/VCO2 ). A different approach for prognostic assessment is the Seattle Heart Failure Model (SHFM), which is based on clinical data and calculates the estimated annual mortality. HYPOTHESIS: Comparison of the prognostic value of the Seattle Heart Failure Score and cardiopulmonary excercis testing in patients with chronic heart failure.
METHODS: One hundred fifty-seven patients with ischemic heart failure and recent intracoronary progenitor cell application were analyzed for mortality during a follow-up of 4 years. CPET (peak VO2 , O2 Pmax, OUES, VE/VCO2 ) was performed in all patients at baseline. The SHFM score was calculated for every patient, with data obtained at the time of CPET.
RESULTS: During follow-up, 24 patients died (15.2%). Nonsurvivors had significantly worse initial CPET results and a higher SHFM score compared to survivors. Receiver operating characteristics curve analysis of sensitivity and specificity revealed the largest area under the curve value for the SHFM score, followed by VE/VCO2 slope. Kaplan Meier analysis using cutoff points of SHFM and VE/VCO2 slope with highest sensitivity and specificity resulted in significant discrimination of survivors and nonsurvivors. By multivariate analysis, only the SHFM score persisted as independent predictor of mortality in these patients.
CONCLUSIONS: These data indicate superior prognostic power of the SHFM score compared to CPET in patients with chronic ischemic heart failure.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23377956      PMCID: PMC6649359          DOI: 10.1002/clc.22093

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Differential prognostic accuracy of right ventricular dysfunction, the Seattle heart failure model and the MAGGIC score in patients with severe mitral regurgitation undergoing the MitraClip® procedure.

Authors:  S Heyl; B Luu; M Wieszner; A Nikkhoo; F Seeger; K Hemmann; B Assmus; B Kaess; A M Zeiher; C Walther; S Fichtlscherer; J Honold
Journal:  Int J Cardiol Heart Vasc       Date:  2020-10-12

2.  Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure.

Authors:  Joerg Honold; Ulrich Fischer-Rasokat; Florian H Seeger; David Leistner; Saskia Lotz; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2013-04-24       Impact factor: 5.460

3.  Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis.

Authors:  Beatrice von Jeinsen; Kateryna Sopova; Lars Palapies; David M Leistner; Stephan Fichtlscherer; Florian H Seeger; Jörg Honold; Stefanie Dimmeler; Birgit Aßmus; Andreas M Zeiher; Till Keller
Journal:  ESC Heart Fail       Date:  2019-03-25

Review 4.  Regenerative Therapy for Cardiomyopathies.

Authors:  Zi Wang; Xuan Su; Muhammad Ashraf; Il-Man Kim; Neal L Weintraub; Meng Jiang; Yaoliang Tang
Journal:  J Cardiovasc Transl Res       Date:  2018-05-09       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.